Mizuho Maintains Outperform on ADMA Biologics, Lowers Price Target to $20

Benzinga Newsdesk www.benzinga.com Negative 94.3%

Neg 94.3% Neu 0% Pos 0%

Mizuho analyst Anthony Petrone maintains ADMA Biologics (NASDAQ:ADMA) with a Outperform and lowers the price target from $24 to $20.